BioNTech与映恩生物合作研发的实验性乳腺癌药物在研究中取得成功,这是双方合作的首个成果。中期分析显示,该药物在治疗乳腺癌方面优于罗氏控股的老牌药物Kadcyla,使用新药的患者病情恶化或死亡风险更低。该试验在中国进行,针对228名癌症已扩散或不适合手术且曾接受过化疗和曲妥珠单抗治疗的患者。此次成功是BioNTech与映恩生物合作开展的首个后期试验成果,也是BioNTech抗癌化合物首次在可能...
Source LinkBioNTech与映恩生物合作研发的实验性乳腺癌药物在研究中取得成功,这是双方合作的首个成果。中期分析显示,该药物在治疗乳腺癌方面优于罗氏控股的老牌药物Kadcyla,使用新药的患者病情恶化或死亡风险更低。该试验在中国进行,针对228名癌症已扩散或不适合手术且曾接受过化疗和曲妥珠单抗治疗的患者。此次成功是BioNTech与映恩生物合作开展的首个后期试验成果,也是BioNTech抗癌化合物首次在可能...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.